Dividend Aristocrat AbbVie (ABBV) will raise its quarterly dividend by 8.5 percent to $1.41 per share in 2021. This comes after a dividend hike of 10.2 percent to $1.30 per share announced in 2020. This marks 50 years in a row of dividend increases by ABBV.

The increased ABBV dividend is payable on February 15, 2022 to shareholders of record as of January 14, 2022. A new annual dividend rate of $5.64 per share yields 4.9% at a stock price of 114.67. AbbVie now pays an estimated $9.96 billion in dividends to shareholders annually.

AbbVie is a research-based biopharmaceutical company. The company has business in therapeutic areas including, eye care, immunology, oncology, virology, women's health, gastroenterology and neuroscience. AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. Abbvie's Humira medicine (for treatment of psoriasis and rheumatoid arthritis) is the world's best selling prescription medicine.  AbbVie became an independent company as a result of the distribution by Abbott Laboratories of 100% of the outstanding common stock of AbbVie to Abbott’s shareholders. In 2019 Abbvie completed the acquisition of Allergan PLC know for its Botox brand.